EU Drug Security: Critical Medicines Act Costs
Europe wants drug security, but the policy path now on the table will not come cheap. After the March 2025 Critical Medicines Act proposal and the 12 May 2026 provisional political agreement, EU institutions are pairing industrial tools with shortage monitoring. The open question is who pays for strategic capacity, diversified APIs, and collaborative procurement.
Contents10 sections
Key Takeaways
- The European Commission proposed the Critical Medicines Act in March 2025 to improve availability, supply, and production of critical medicines in the EU.
- On 12 May 2026, EMA welcomed a provisional Parliament–Council agreement on the Act and said it complements the revised EU pharmaceutical legislation.
- EMA reports the Union list of critical medicines covers over 200 active substances; list version 2.1 was last updated on 19 January 2026.
- Cost pressure sits in strategic projects, state-aid support, and procurement redesign rather than in a single published EU budget line for the Act.
EU drug-security toolkit at a glance
| Instrument | Status in primary sources | Cost / capacity signal |
|---|---|---|
| Critical Medicines Act | Proposed March 2025; provisional political agreement welcomed by EMA on 12 May 2026 | Strategic projects, state aid, collaborative procurement |
| Pharma legislation reform | Political agreement welcomed by Commission in December 2025 | Faster access, shortage monitoring, generic entry rules |
| Union list of critical medicines | Version 2.1 (rev. 1), last updated 19 January 2026 | Prioritises >200 active substances for supply actions |
| MSSG vulnerability work | EMA says MSSG is assessing a first set of listed medicines | Feeds strategic-project and procurement choices |
What is the Critical Medicines Act trying to buy?
The Commission’s public-health page states that in March 2025 it proposed the Critical Medicines Act to improve the availability, supply, and production of critical medicines within the EU. It also targets access to medicines of common interest, including some rare-disease products that are missing in certain markets, according to the Commission Critical Medicines Act overview.
Key features listed by the Commission include designation of Strategic Projects with easier funding access and fast-tracked procedures; public procurement that rewards supply-chain resilience; Commission-supported collaborative procurement among Member States; exploration of international partnerships to reduce single-supplier dependence; and state-aid guidelines for national financing of strategic projects.
Those are industrial-policy tools, not just labelling changes. If Europe wants more local or diversified manufacturing of critical products and APIs, someone must finance plants, dual sourcing, stockpiles, and less price-only tendering.
Why did EMA call the May 2026 deal a milestone?
On 12 May 2026, EMA published a news note welcoming the provisional agreement reached by the European Parliament and the Council on the Critical Medicines Act. Executive Director Emer Cooke said resilient and secure supply chains for critical medicines are essential amid increasing global disruptions, per EMA's 12 May 2026 Critical Medicines Act statement.
EMA frames the Act as combining regulatory tools with targeted industrial measures. It says the CMA builds on EMA’s extended mandate and complements measures in the revised EU pharmaceutical legislation. It also notes aims to improve access to medicines of common interest that may be unavailable in some EU markets.
For operators, the practical signal is that shortage policy is no longer only a pharmacovigilance or notification issue. It is becoming a standing industrial and procurement agenda with EMA as an implementing partner.
How does the Union critical list set the spending priority?
EMA, the Heads of Medicines Agencies, and the Commission use the Union list of critical medicines to take proactive measures against shortages. The current file is “Union list of critical medicines - version 2.1 (revision 1),” reference EMA/361872/2025, first published 12 December 2025 and last updated 19 January 2026, according to EMA's Union list of critical medicines page.
In its May 2026 CMA note, EMA says the list contains over 200 active substances of medicines for human use considered critical for healthcare systems across the EU. Medicines on the list are prioritised for EU-wide actions to strengthen supply chains.
That matters for cost because a finite list focuses scarce capital. Strategic-project money, vulnerability assessments, and tougher procurement criteria will land first on listed products, not on every authorised medicine.
Where do vulnerability assessments and ESMP fit?
EMA says the Act foresees a role for its Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) in carrying out supply-chain vulnerability assessments. Those assessments are meant to inform measures under both the new pharmaceutical legislation and the CMA, including strategic projects and public procurement procedures.
EMA also says that, in preparation for CMA implementation, the MSSG is already evaluating vulnerabilities in the supply chains of a first set of medicines on the Union list. In parallel, EMA is expanding the European Shortages Monitoring Platform (ESMP) to enable faster, more consistent, data-driven exchanges on potential shortages between industry and regulators.
Monitoring itself is not free. Companies face denser reporting expectations; agencies need platform capacity; and Member States need staff to act on alerts. Those are recurring operating costs layered on top of any factory investment.
How does pharma-law reform reinforce sovereignty goals?
The Commission’s reform page says that in December 2025 it welcomed political agreement to modernise EU pharmaceutical legislation that is about 20 years old. Stated aims include faster patient access, streamlined procedures, stronger innovation incentives, better shortage monitoring and coordination, and clearer patent exemptions that support timely generic entry, per the Commission reform of EU pharmaceutical legislation page.
EMA’s CMA note explicitly treats the Act and the revised pharmaceutical legislation as complementary. One package leans industrial and procurement; the other rewires authorisation, incentives, and shortage obligations. Together they are the legal chassis for “strategic autonomy” language in medicines policy.
For generics and hospital buyers, clearer shortage duties and collaborative procurement can raise reliability. For innovators, faster pathways may help, but resilience criteria in tenders can also change winning bids away from lowest unit price alone.
What remains unpriced in the official record?
None of the Commission or EMA pages cited here publish a single euro total for implementing the Critical Medicines Act across the Union. The cost case is structural: strategic projects need funding access; state-aid guidelines exist to help Member States finance them; collaborative procurement can trade unit price for multi-winner or resilience criteria; and international partnerships are meant to diversify, not necessarily cheapen, supply.
Readers should also separate proposal text from final adopted law. As of the 12 May 2026 EMA note, the Parliament–Council deal was a provisional political agreement. Final legal text, delegated acts, and national financing choices will decide how expensive “drug security” becomes in practice.
Related NovaPharma coverage includes the EU Commission and EMA 2026 drug report findings, PRAC June 2026 safety highlights, and Vanda's EMA orphan-designation positive opinion.
Frequently Asked Questions
What did the May 2026 Critical Medicines Act deal change?
On 12 May 2026, EMA welcomed a provisional agreement between the European Parliament and the Council on the Critical Medicines Act. The deal backs tools to improve availability, production, and supply of critical medicines, and complements the reformed EU pharmaceutical legislation.
How does the Union list of critical medicines fit in?
EMA, HMA, and the Commission use the Union list to prioritise EU-wide supply actions. Version 2.1 (revision 1) was last updated on 19 January 2026. EMA says the list contains over 200 active substances considered critical for healthcare systems across the EU.
Why is EU drug security unlikely to come cheap?
Commission materials frame shortages as driven by manufacturing problems, supply-chain risk, and global competition for resources. The Act leans on strategic projects, state-aid support, collaborative procurement, and diversification. Those tools imply higher public and industrial spending to rebuild capacity, even though no single official price tag for the full package appears in the cited primaries.
Primary Sources
This article follows our editorial standards. Report a correction via editorial contact.
Pharmaceutical Intermediates Market to Reach $57 Billion by 2035 as Generic Drug Manufacturing Drives 4.5% Annual Growth
Lung Cancer Therapeutics Market to Hit $142.3 Billion by 2036 as Precision Medicine Drives 11.8% Growth
Vabysmo Market Report 2026: Roche's Eye Drug Shows Strong Growth Through 2035 Amid Rising Retinal Disorder Cases